1. Anticoagulation Use and Endovascular Thrombectomy in Patients with Large Core Stroke: A Secondary Analysis of the SELECT2 Trial.
- Author
-
Pujara, Deep K., Hussain, M. Shazam, Abraham, Michael G., Ortega‐Gutierrez, Santiago, Chen, Michael, Kasner, Scott E., Churilov, Leonid, Sitton, Clark W., Blackburn, Spiros, Sundararajan, Sophia, Hu, Yin C., Herial, Nabeel A., Budzik, Ronald F., Hicks, William J., Arenillas, Juan F., Tsai, Jenny P., Kozak, Osman, Cordato, Dennis J., Manning, Nathan W., and Hanel, Ricardo A.
- Subjects
INTRACRANIAL hemorrhage ,ENDOVASCULAR surgery ,ANTICOAGULANTS ,CONGESTIVE heart failure ,ORAL medication - Abstract
Endovascular thrombectomy (EVT) safety and efficacy in patients with large core infarcts receiving oral anticoagulants (OAC) are unknown. In the SELECT2 trial (NCT03876457), 29 of 180 (16%; vitamin K antagonists 15, direct OACs 14) EVT, and 18 of 172 (10%; vitamin K antagonists 3, direct OACs 15) medical management (MM) patients reported OAC use at baseline. EVT was not associated with better clinical outcomes in the OAC group (EVT 6 [4–6] vs MM 5 [4–6], adjusted generalized odds ratio 0.89 [0.53–1.50]), but demonstrated significantly better outcomes in patients without OAC (EVT 4 [3–6] vs MM 5 [4–6], adjusted generalized odds ratio 1.87 [1.45–2.40], p = 0.02). The OAC group had higher comorbidities, including atrial fibrillation (70% vs 17%), congestive heart failure (28% vs 10%), and hypertension (87% vs 72%), suggesting increased frailty. However, the results were consistent after adjustment for these comorbidities, and was similar regardless of the type of OACs used. Whereas any hemorrhage rates were higher in the OAC group receiving EVT (86% in OAC vs 70% in no OAC), no parenchymal hemorrhage or symptomatic intracranial hemorrhage were observed with OAC use in both the EVT and MM arms. Although we did not find evidence that the effect was due to excess hemorrhage or confounded by underlying cardiac disease or older age, OAC use alone should not exclude patients from receiving EVT. Baseline comorbidities and ischemic injury extent should be considered while making individualized treatment decisions. ANN NEUROL 2024;96:887–894 [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF